Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Emory University
New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.
The MET inhibitor already pending US FDA approval had good results in patients with brain metastases. Spectrum’s TKI inhibitor poziotinib continues to be studied after Cohort 1 failure.
Recent collaborations involving Ridgeback, Themis, Junshi, Moleculin, Can-Fite, Pluristem and Beroni highlight the intense increase in research in how to treat or prevent COVID-19.
Private Company Edition: Deerfield is funding a new life science campus. Also, BioFractura gets up to $67.4m in BARDA contract in recent grant and government deal surge, Mission Bay raises a $60m fund and Amphivena closes a $62m VC round.
- Academic and Research Institutions